SCHEMBL5451109

SCHEMBL5451109

NC(=O)c1c(NC(=O)Nc2ccccc2)sc2cc(O)ccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.56
KMT2A Q03164 6/20 0.56
MAPT P10636 5/20 0.56
RAB9A P51151 4/20 0.56
NPC1 O15118 3/20 0.56
ALDH1A1 P00352 2/20 0.56
GAA P10253 1/20 0.56
DYRK1A Q13627 4/20 0.51
DYRK1B Q9Y463 2/20 0.51
MAOA P21397 1/20 0.48
MAOB P27338 1/20 0.48
EPHB4 P54760 1/20 0.46
TRPV1 Q8NER1 1/20 0.45
TNIK Q9UKE5 1/20 0.44
CYP1A2 P05177 2/20 0.43
KDM4E B2RXH2 1/20 0.43
TP53 P04637 1/20 0.42
EPHX1 P07099 1/20 0.42
TSHR P16473 1/20 0.42
EPHX2 P34913 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17625475 0.88 MEN1 (0.52) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL5447596 0.88 GAA (0.48) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL5456326 0.88 MEN1 (0.43) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL5458283 0.88 MEN1 (0.43) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL5459965 0.88 MDM2 (0.45) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL5453616 0.87 TRPV1 (0.51) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL5453364 0.86 MEN1 (0.48) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL5455604 0.85 MAPT (0.48) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL5455862 0.85 BAZ1A (0.51) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL17625474 0.85 CA12 (0.43) MEN1KMT2AMAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 MEN1 2891/4885KMT2A 4785/4885MAPT 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.